AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02208037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (ARM with Maraviroc)
Description: Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of maraviroc. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
Study NCT02208037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (ARM with Bortezomib)
Description: Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of bortezomib. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
Study NCT02208037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc will be dosed at 300 mg orally twice a day and will start on Day -3 prior to hematopoietic stem cell infusion, and continue until Day 30 post HSCT. If the patient requires a two-day stem cell infusion, maraviroc treatment will end 30 days after the first infusion day.
Study NCT02208037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered at the dose of 1.3 mg/m2 based upon actual body weight (ABW) as an approximately 3-5 second IV push on Days +1, +4, and +7 after hematopoietic stem cell infusion. There must be at least 72 hours between each dose of bortezomib. Subcutaneous administration of bortezomib is not allowed on this protocol.
Study NCT02208037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: MMF will be given at a dose of 15 mg/kg three times a day (TID) based upon ABW with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day 5 and discontinue after the last dose on Day 35, or may be continued if active GVHD is present.
Study NCT02208037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Hydration prior to cyclophosphamide may be given according to institutional standards.~Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide \[50 mg/kg ideal body weight (IBW); if ABW \< IBW, use ABW\] will be given on Day 3 post-transplant (between 60 and 72 hours after the start of the HSCT) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
Study NCT01043445 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GPR 119 agonist, 2-oleyl glycerol
Description: Emulgation, 50 ml. containing 2g 2OG
Study NCT01043445 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oleic acid
Description: Emulgation, 50 ml. containing 1.54g of oleic acid
Study NCT01043445 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol
Study NCT01043445 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Description: Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol
Study NCT01043445 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol
Study NCT04889859 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: long Roux limb Roux-en-Y reconstruction
Description: After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 100 cm-long Roux limb and 50 cm-long biliopancreatic limb.
Study NCT04889859 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: long biliopancreatic limb Roux-en-Y reconstruction
Description: After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 50 cm-long Roux limb and 100 cm-long biliopancreatic limb.
Study NCT00721032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI guided VT ablation
Description: Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia (VT)
Study NCT00721032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Increased dose of amiodarone
Description: Increase the dose of amiodarone according to the following scheme:~current dose -> new dose 100 once daily (QD) -> 200 QD; 200 QD -> 400 QD; 300 QD -> 600 QD; 400 QD -> 600 QD
Study NCT02215954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999169
Description: FE 999169 is a white crystalline powder for oral solution. Each sachet (16.1 g) contains sodium picosulfate hydrate 10 mg, magnesium oxide 3.5 g and anhydrous citric acid 12 g as well as orange flavour, potassium bicarbonate and sodium saccharin as excipients. FE 999916 is dissolved by mixing the contents of the sachet with approximately 150mL of cold water in a cup before administration.
Study NCT02215954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niflec
Description: Niflec is a white-yellowish powder for oral solution. Each plastic sachet (137.155 g) contains sodium chloride 2.93 g, potassium chloride 1.485 g, sodium bicarbonate 3.37 g and sodium sulfate anhydrous 11.37 g, as well as macrogol 4000, saccharin sodium hydrate, flavour as excipients. Niflec is dissolved in water to make approximately 2 L of solution before administration.
Study NCT03409562 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motor control training
Description: Exercises to strengthen the lumbar musculature and control the posture.
Study NCT03409562 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: motor control training
Description: Exercises to strengthen the lumbar musculature and control the posture.
Study NCT03409562 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pain neurophysiology education
Description: Educational sessions to improve patient's neurophysiology of pain knowledge.
Study NCT00585975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bromfenac ophthalmic solution
Description: sterile opthalmic solution
Study NCT00726713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metanx (a medical food)
Description: Metanx one tablet twice a day
Study NCT00726713 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Metanx placebo
Description: Metanx placebo one tablet twice a day
Study NCT00376012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)
Description: Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 4 months.
Study NCT00376012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)
Description: Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 7 months.
Study NCT04456712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 400 MG/200 ML Intravenous Solution
Description: antibiotic
Study NCT04456712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 MG
Description: antibiotic
Study NCT00498615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasudil
Description: Each subject will be randomly assigned to 1 of 6 possible treatment sequences (ABC, ACB, BAC, BCA, CAB, and CBA) in a double-blind manner: A- a single oral dose of 2 placebo tablets; B- a single, oral 40 mg Fasudil dose as one 40 mg tablet and 1 placebo tablet; C- a single oral 80 mg dose as two 40 mg Fasudil tablets. Subjects will be randomized at the screening/baseline visit to a specific treatment sequence based upon a computer generated code on a 1:1:1:1:1:1 ratio for the 6 possible sequences. A single dose consisting of the two tablets will be taken after fasting for 10 hours once during each treatment period. A washout interval of at least 24 hours and no more than 7 days will be maintained between treatment periods. Concomitant medications will not be taken during the study session.
Study NCT00498615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fasudil
Description: Each subject will be randomly assigned to 1 of 6 possible treatment sequences (ABC, ACB, BAC, BCA, CAB, and CBA) in a double-blind manner: A- a single oral dose of 2 placebo tablets; B- a single, oral 40 mg Fasudil dose as one 40 mg tablet and 1 placebo tablet; C- a single oral 80 mg dose as two 40 mg Fasudil tablets. Subjects will be randomized at the screening/baseline visit to a specific treatment sequence based upon a computer generated code on a 1:1:1:1:1:1 ratio for the 6 possible sequences. A single dose consisting of the two tablets will be taken after fasting for 10 hours once during each treatment period. A washout interval of at least 24 hours and no more than 7 days will be maintained between treatment periods. Concomitant medications will not be taken during the study session.
Study NCT04540562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD app
Description: The COPD app consisted of an 8 week self-management program. The app had three views: timeline, information page, and contact page. The timeline was classified in 8 weeks, and each week included the lung exacerbation plan, daily and extra medication, information and education and questionnaires. The first week also included a video of a pulmonologist explaining the purpose of the app and additional information about the functionalities of the COPD app. A video consultation was planned after after 4 weeks and a face-to-face consultation after 8 weeks.
Study NCT01337375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa 2a [Pegasys]
Description: sc weekly
Study NCT01337375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: iv weekly
Study NCT01337375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: sc twice weekly
Study NCT01337375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: iv twice weekly
Study NCT04786756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: 1 mg/kg Bupivacaine (0.25%)
Study NCT03414047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Administered IV
Study NCT04560478 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pro Seal Sealant
Description: Sealant was reapplied every 3 months
Study NCT04560478 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MI Varnish
Description: Fluoride varnish was applied every 4-6 weeks
Study NCT03530462 — intervention group
Intervention type: DRUG
Intervention: rituximab
Description: 375 mg/m2 weekly for 4 weeks
Study NCT03530462 — intervention group
Intervention type: DRUG
Intervention: cyclophosphamide
Description: 750 mg/m2 monthly for 4-6 cycles depending on the response
Study NCT03530462 — intervention group
Intervention type: DRUG
Intervention: Steroids
Description: 500-1000 mg of methylprednisolone daily for 3 days, then tapered doses
Study NCT03530462 — intervention group
Intervention type: DRUG
Intervention: Intravenous immunoglobulin
Description: intravenous immunoglobulin (IVIG) with or without plasmapheresis
Study NCT00926380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab
Description: denosumab: 60 mg SC every 6 months
Study NCT00926380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: teriparatide: 20 mcg SC QD
Study NCT01321723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTH analog
Description: A recombinant 1-31 amino acid fragment of PTH.
Study NCT01321723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01321723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Forsteo (Teriparatide)
Description: A recombinant 1-34 amino acid fragment of PTH.
Study NCT05623813 — intervention group
Intervention type: OTHER
Intervention: Postoperative education
Description: provide patients with the understanding and confidence to safely engage in their daily activities whilst following post-sternotomy precautionary guidelines throughout their recovery
Study NCT00713206 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implant (Osseotite)
Description: Root form titanium dental implant
Study NCT03516045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AlF-NOTA-neurotensin
Description: One injection of the radioligand 18F-AlF-NOTA-neurotensin
Study NCT06295042 — intervention group
Intervention type: OTHER
Intervention: BREAST-Q Questionnaire
Description: Patient-reported outcome measure
Study NCT02062112 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pattern of flavoring of bowel laxative
Description: Unflavored bowel laxative versus entire bowel laxative flavored versus liberal flavoring as decided by patient
Study NCT02134366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam
Description: Comparison of AED use in Epilepsia Partialis Continua
Study NCT02134366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobazam
Description: Comparison of AED use in Epilepsia Partialis Continua
Study NCT02134366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: Comparison of AED use in Epilepsia Partialis Continua
Study NCT02134366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonazepam
Description: Comparison of AED use in Epilepsia Partialis Continua
Study NCT02134366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Comparison of AED use in Epilepsia Partialis Continua
Study NCT02134366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Comparison of AED use in Epilepsia Partialis Continua
Study NCT04693910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimedia-Based Hormone Therapy Information Program
Description: The multimedia hormone therapy information program lasted 6 weeks and covered 6 topics, namely the recognition of hormone therapy and multimedia information programs, mindfulness, exercise, stress relief, positive thinking, and prevention or reduction of fatigue.
Study NCT04672798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRITEPath
Description: BRITEPath will guide co-located mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.
Study NCT04672798 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: Participants in this group will receive usual care from their mental health care provider.
Study NCT02550483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Base diet + high beta-carotene tomato juice
Description: Participants will receive high beta-carotene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
Study NCT02550483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Base diet + high lycopene tomato juice
Description: Participants will receive high lycopene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
Study NCT02550483 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Base diet + placebo beverage
Description: Participants will receive a placebo beverage daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
Study NCT01963715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGN289
Study NCT03211728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: The intervention group receive pregabalin 150 mg 1 hour before surgery and 12 hours after initial dose.
Study NCT01232374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 200mg (4 bottles), once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
Study NCT01232374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
Study NCT01232374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
Study NCT01232374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
Study NCT01232374 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.~Placebo: 4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
Study NCT01232374 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.~Placebo: 4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
Study NCT01027897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: Doripenem 1 gm administered over 4 hours X 3 doses
Study NCT04757233 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: GlucoType
Description: GlucoType is an mobile Health intervention for facilitating self-management in T2DM built for iPhone and Android smartphones. GlucoType includes a custom-built interface for low-burden capture of diet and blood glucose (BG) levels and relies on a commercial activity tracker, FitBit, for capture of sleep and physical activity. It then applies computational phenotyping techniques to identify patterns of associations between daily activities and changes in BG levels. GlucoType uses an expert system developed by our research team to translate identified phenotypes into automatically-generated personalized behavioral goals for improving glycemic control formulated in natural language.
Study NCT04343365 — intervention group
Intervention type: OTHER
Intervention: Evolutionary Tumor Board (ETB)
Description: The ETB consists of evolutionary biologists, mathematicians, research scientists, statisticians,data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators.The ETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The ETB will collect data through a chart review regarding adherence and results of ETB recommendation
Study NCT02634710 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Treatments will have a minimum of a 48-hour interfraction interval. Treatments will be completed over 20 days maximum.